158 related articles for article (PubMed ID: 33103527)
1. Circulating microRNA-145 as a diagnostic biomarker for non-small-cell lung cancer: A systemic review and meta-analysis.
Tao S; Ju X; Zhou H; Zeng Q
Int J Biol Markers; 2020 Dec; 35(4):51-60. PubMed ID: 33103527
[TBL] [Abstract][Full Text] [Related]
2. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
3. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.
Zhang ZJ; Song XG; Xie L; Wang KY; Tang YY; Yu M; Feng XD; Song XR
Exp Biol Med (Maywood); 2020 Oct; 245(16):1428-1436. PubMed ID: 32741216
[TBL] [Abstract][Full Text] [Related]
4. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
Yuxia M; Zhennan T; Wei Z
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2045-50. PubMed ID: 22806310
[TBL] [Abstract][Full Text] [Related]
5. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
6. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of the diagnostic value of circulating microRNA-17-5p in patients with non-small cell lung cancer.
Hao J; Shen Z
Medicine (Baltimore); 2023 Feb; 102(8):e33070. PubMed ID: 36827064
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies.
Chen L; Jin H
Tumour Biol; 2014 Sep; 35(9):9119-29. PubMed ID: 25027397
[TBL] [Abstract][Full Text] [Related]
9. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
10. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer.
Peng H; Wang J; Li J; Zhao M; Huang SK; Gu YY; Li Y; Sun XJ; Yang L; Luo Q; Huang CZ
Life Sci; 2016 Apr; 151():235-242. PubMed ID: 26946307
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
[TBL] [Abstract][Full Text] [Related]
12. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.
Halvorsen AR; Bjaanæs M; LeBlanc M; Holm AM; Bolstad N; Rubio L; Peñalver JC; Cervera J; Mojarrieta JC; López-Guerrero JA; Brustugun OT; Helland Å
Oncotarget; 2016 Jun; 7(24):37250-37259. PubMed ID: 27191990
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
[TBL] [Abstract][Full Text] [Related]
15. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P
Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397
[No Abstract] [Full Text] [Related]
17. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
18. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
19. Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab.
Zhou F; Lu X; Zhang X
Cardiovasc Toxicol; 2018 Jun; 18(3):284-289. PubMed ID: 29737469
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer.
Zou JG; Ma LF; Li X; Xu FL; Fei XZ; Liu Q; Bai QL; Dong YL
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1108-1115. PubMed ID: 30779079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]